Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative disorders of the central nervous system. Its news flow centers on the clinical and regulatory progress of its lead candidate, zervimesine (CT1812), an investigational oral pill in development for Alzheimer’s disease, dementia with Lewy bodies (DLB) and related conditions.
News updates from Cognition Therapeutics frequently cover milestones in its Phase 2 clinical programs. These include results and analyses from the SHINE study in mild-to-moderate Alzheimer’s disease, the SHIMMER study in mild-to-moderate DLB, and the START study in early Alzheimer’s disease. Articles describe safety and tolerability outcomes, changes in cognition and function measured by validated scales, and exploratory findings in behavioral, movement and neuropsychiatric domains.
Investors following CGTX news also see announcements about expanded access programs for zervimesine in DLB, collaborations with organizations such as the Alzheimer’s Clinical Trials Consortium, and substantial grant support from the National Institute on Aging of the National Institutes of Health. Regulatory and scientific updates, such as end-of-Phase 2 discussions with the U.S. Food and Drug Administration, Type C meeting plans, and presentations at major Alzheimer’s disease conferences, are regular features of the company’s news cycle.
In addition, Cognition Therapeutics issues press releases on financing transactions, including registered direct offerings of common stock and at-the-market equity programs, which provide context on how it funds ongoing and planned studies. For readers tracking CGTX, this news page consolidates clinical, regulatory, scientific and capital markets developments related to zervimesine and the company’s broader neurodegenerative disease pipeline.
Cognition Therapeutics (Nasdaq: CGTX), a clinical-stage biopharmaceutical company, has announced it will release its Q2 2024 financial results on August 8, 2024, before market open. The company will host a conference call and live audio webcast at 8:30 a.m. ET on the same day to discuss the results and provide a business update.
Cognition Therapeutics focuses on developing treatments for neurodegenerative disorders. Their lead candidate, CT1812, is being investigated for Alzheimer's disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD). The company believes CT1812 and its pipeline of σ-2 receptor modulators can regulate impaired pathways in these diseases, offering a potentially distinct approach from other treatments in development.
Cognition Therapeutics (NASDAQ: CGTX) reported positive results from its Phase 2 SHINE trial for CT1812, an oral treatment for mild-to-moderate Alzheimer's disease. The study showed:consistent cognitive improvement compared to placebo across all measures, with a ~40% mean improvement in cognitive outcomes. CT1812 demonstrated a favorable safety profile with mostly mild or moderate adverse events. Significant changes were observed in neurofilament light chain, a marker of neurodegeneration. The 100mg dose showed particularly promising results, informing future dose selection. These findings suggest that CT1812's amyloid oligomer antagonism mechanism may have potential as a monotherapy or in combination with approved drugs for Alzheimer's and related dementias.
Cognition Therapeutics (NASDAQ: CGTX) will host an investor webcast on July 29, 2024, to discuss results from the Phase 2 SHINE study of CT1812 in mild-to-moderate Alzheimer's disease. The study enrolled 153 adults, randomized to receive 100mg or 300mg of CT1812 or placebo daily for six months. Clinical findings, safety, cognitive and functional endpoints will be presented at the Alzheimer's Association's International Conference in Philadelphia. Additional presentations will cover biomarker and proteomic analyses from CSF samples, and results of a meta-analysis from the SPARC study and SHINE-A participants. The webcast will feature company management, study investigator Dr. Everard Vijverberg, and Alzheimer's expert Dr. Martin J. Sadowski.
Cognition Therapeutics (NASDAQ: CGTX) announced that their Phase 2 SHINE study results for CT1812, a drug targeting mild-to-moderate Alzheimer’s disease, will be presented at the Alzheimer’s Association's International Conference (AAIC) in Philadelphia from July 28 to August 1, 2024.
The study's abstracts cover clinical efficacy, safety, and biomarker findings. Key abstracts include:
- Clinical efficacy results from the Phase 2 SHINE study (Abstract #89115).
- CSF phosphoproteomics biomarker analysis (Abstract #95147).
- Topline CSF biomarker outcomes (Abstract #95767).
- Exploratory CSF proteomics biomarker outcomes (Abstract #95770).
Cognition will also provide additional information about their Alzheimer’s disease program and CT1812 at booth #731 in the Exhibit Hall.
Cognition Therapeutics (NASDAQ: CGTX) released the eighth episode of its Conversations video podcast titled “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode explores how beta amyloid (Aβ) oligomers lead to synaptic dysfunction and cognitive decline. The podcast discusses recent research showing Aβ oligomers binding to synapses in Alzheimer's patients and how CT1812 can reverse this binding and reduce toxicity. Highlights include the use of quantitative EEG as a biomarker in the Phase 2 ‘SEQUEL’ study, which showed improvements in synaptic function and brain connectivity after four weeks of CT1812 treatment. Dr. Hamby presented proteomic analysis results demonstrating CT1812's positive effects on proteins and pathways linked to Alzheimer's. The discussion was moderated by Dr. Anthony Caggiano, featuring Dr. Mary Hamby, Dr. Everard Vijverberg, and Dr. Tara Spires-Jones.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) reported financial results for Q1 2024 and provided business updates. They completed enrollment of 130 participants in the SHIMMER study for Alzheimer's and DLB, with topline results expected mid-2024. The company also raised $11.9 million in a public offering and presented research findings at conferences.
Financially, the company has $34.7 million in cash and $62.3 million in grant funds. Research and development expenses increased to $10.6 million, leading to a net loss of $9.2 million for the quarter.
Cognition Therapeutics, Inc. completed enrollment in the Phase 2 SHIMMER study of CT1812 for mild-to-moderate dementia with Lewy bodies. Top-line results are expected in the second half of 2024. The study aims to develop a disease-modifying therapy for DLB by targeting Aβ and α-synuclein oligomers.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of COGNITION THERAPEUTICS (CGTX)?
What is the market cap of COGNITION THERAPEUTICS (CGTX)?
